Laboratory Prognostic Index (LAB-PI) in DLBCL: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI in @ESMO_Open. High LDH, low Hb & high B2M predict prognosis of newly diagnosed DLBCL. https://t.co/UEqLKr2jcV

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial in @ESMO_Open. Robust activity in MSI CRC, limited in MSI-Like MSS. https://t.co/MSmjzHRrOf

Stripe offered to acquire us for $1.2 billion when we had $2M in revenue. Today, we've raised $330M at an $8B valuation and reached $1B ARR. We could've died three times during this journey. This is the story I've never told anyone before:

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX) in @ESMO_Open. Short-course denosumab is associated with reduced distant relapse risk, warranting further exploration. https://t.co/i57uKFdeum

Radiomic signatures to estimate survival in patients with advanced HCC treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance) in @ESMO_Open. AI-driven radiomic-clinical model can accurately predict OS as early as 10 weeks into treatment. https://t.co/QoFJGU4sS6

2nd-line 5-FU + NAIRI vs FOLFOX/XELOX in metastatic #PADC after gem—nab-pacli: propensity score-matched analysis @ESMO_Open https://t.co/n1g0vROoUo 👉mOS 7.2 vs 5.8 mo 👉mPFS 3.0 vs 2.5 mo 👉more side effects for Naliri 🧐still devastating poor outcome, we need to do better...

The plan was clean. The escape? Not so much. Midway City doesn’t play fair. Wishlist this 4-player coop heist FPS on Steam today.

Outcomes of ICI rechallenge in advanced urothelial carcinoma: results from a global RW evidence study in @ESMO_Open. Retrospective data suggesting some patients could benefit from this treatment. Different ICI sequencing may act differently. https://t.co/ogaBwkSWzl

Pembrolizumab plus chemotherapy vs chemotherapy for advanced esophageal cancer: 5-year extended f-up for the randomized phase III KEYNOTE-590 study in @ESMO_Open. Durable efficacy of chemo-IO, 5-yrs survival rate of 10.6% vs 3.0% & no new safety signals. https://t.co/yYvHt9NmJh

Meta-analysis of surrogate endpoints for overall survival in extensive-stage small-cell lung cancer in @ESMO_Open. PFS shows strong correlation with OS in 1L trials, while neither ORR nor DCR predicts survival. In 2L, DCR correlates with PFS but not OS. https://t.co/rnEJCAfJBy

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers in @ESMO_Open. EV shows activity especially in patients with esophageal squamous cell carcinoma, with expected safety profile. https://t.co/68WpG9bbCH

Our average cost per month for CrowdHealth hit its lowest EVER in 2025!!! $140.42/month for singles <55 (down 13% vs '24) $225.83/month for singles 55+ (down 17% vs '24) $476.25/month for families of 4 (down 11% vs '24) If you are looking for an affordable alternative to health

Just ahead of #ESMO25 Our new paper in @ESMO_Open shows that short preoperative ET provides a low-cost, RW tool to assess endocrine sensitivity in ER+ BC Achieving CCCA (Ki67 ≤2.7%) predicts better outcomes (HR 0.19). 🧬 Dynamic biomarkers matter. 🔗 https://t.co/ISR1cuRpTT

Venous thromboembolic event risk with PARPi in solid tumors: a systematic review and meta-analysis in @ESMO_Open. Potential small increased VTE risk, influenced by cancer subtype (higher in pancreatic and prostate cancers) and treatment combinations. https://t.co/kJqOm6xxwT

AI defines spatial patterns of TILs highly associated with outcome – a pan-GI cancer study in @ESMO_open. Spatial TIL-tumor patterns, tumor nuclei shape & texture features on HE WSI as top prognostic features across GI tumors, with generalizability in CRC. https://t.co/oQxNnRoDlq

The rising tides of cancers among young adults in @ESMO_Open. Global rise in early-onset cancers among young adults. This growing trend is a critical scientific challenge requiring an urgent comprehensive in-depth investigation. https://t.co/42MWp1j1xF

Don’t be the one who missed algoland Finish your remaining quests and lock in extra entries for the grand prize

Durvalumab after RT in pts with unresectable stage III NSCLC ineligible for CT: the DUART ph II nonrandomized controlled study in @ESMO_Open. Well tolerated Tx in this frail population. Encouraging activity signals, molecular remission in some cases. https://t.co/ed1TjhEtzM

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study in @ESMO_Open. cfDNA NGS analysis enables early resistance detection and guides personalized ALK TKI therapy. https://t.co/f908Vw8yka

FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and IHC profiling in @ESMO_Open. CRC FGFR profiling (n=7,606) spots aggressive FGFR1-amp tumors. Possible screening by novel IRS IHC method. https://t.co/NpiOzoc7k0

Network analysis of NRG1 VUSes in advanced NSCLC and their prognostic role in EGFR-mutant pts treated with 1L osimertinib in @ESMO_Open. 8% of pts harbour NRG1 VUSes, 57.1% with oncogenic alterations. Potential poor prognostic factor in EGFR+ subgroup. https://t.co/6WVE6bTEye

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study @ESMO_Open

Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial @ESMO_Open

Improving chemotherapy-induced peripheral neuropathy in cancer patients using a combined qigong and self-administered acupressure intervention: a randomized controlled trial - @ESMO_Open